Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-30T19:09:56.719Z Has data issue: false hasContentIssue false
  • English
  • Français

Attenuation in the Progression of Cognitive Deterioration in Alzheimer's Disease With Rivastigmine: A Dose-Dependent Effect

Published online by Cambridge University Press:  07 November 2014

Martin Farlow ,
John Messina ,
Ravi Anand ,
Richard Hartman  and
Jeffrey Veach
Martin Farlow
Affiliation:
Department of Neurology, Indiana University School of Medicine
John Messina
Affiliation:
Novartis Pharmaceuticals Corporation
Ravi Anand
Affiliation:
Novartis Pharmaceuticals Corporation
Richard Hartman
Affiliation:
Novartis Pharmaceuticals Corporation
Jeffrey Veach
Affiliation:
Novartis Pharmaceuticals Corporation
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: Possible disease-modifying effects of rivastigmine have been suggested by analyses using a variation of the randomized start design; however, the results were somewhat confounded by differing attrition rates. We report on an alternative method investigating whether increasing doses reduce the rates of cognitive decline in patients who continue treatment.

Methods: The effect of dose on the rate of cognitive decline seen on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) was explored for patients in a long-term (130-week) extension of a 26-week placebo-controlled trial using two methods: a weighted leas squares regression analysis using each individual's slope, and a weighted analysis of variance (ANOVA) comparing the slopes of patients categorized by dose (≤6 mg/d or >6 mg/d).

Results: The results from 408 patients included in the weighted least squares analysis estimated the rate of decline to attenuate by approximately 1 point/y for every 3 mg/d increase (P<.0001). The average annual rate of decline for patients whose mean dose was >6 mg/d was 4.5 points (95% Cl, 5.1–3.9), while for patients with a mean dose of≥6 mg/d a decline of 8.2 points (95% Cl, 9.1–7.3) was seen.

Conclusion: These data further support earlier results suggesting that rivastigmine reduces the rate of progression of cognitive deterioration in Alzheimer's disease.

Type
Briefs from the Fields of Neurology & Neuropsychiatry
Information
CNS Spectrums , Volume 5 , Issue 6: Toward a Fresh Understanding of ADHD , June 2000 , pp. 21 - 22
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Leber, P. Alzheimer Dis Assoc Disord. 1997:11(suppl 5):S10–21; discussion, S37–39.Google Scholar
2.Messina, J, Sohn, H, Hartman, R. Third International Meeting for the College of Psychiatric and Neurologic Pharmacists. April 6–9, 2000. Washington, DC.Google Scholar
3.Corey-Bloom, J, Anand, R, Veach, J for the ENA 713 B352 Study Group. Int J Geriatr Psychopharmacol. 1998;1:55–65.Google Scholar